The relevance of creating a new combined ophthalmic drug with anti-inflammatory and antibacterial effects
DOI:
https://doi.org/10.14739/2409-2932.2025.2.325216Keywords:
ophthalmology, combined drugs, combat eye injuries, antibacterial drugs, anti-inflammatory drugs, antifungal drugs, eye drops, antibiotics, sulfonamides, drug standardization, pharmaceutical development, eye treatment, eye injuriesAbstract
In the conditions of the full-scale invasion of the Russian Federation into Ukraine, the number of eye injuries and burns has significantly increased, which is the biggest problem of modern civilian and military medicine. The surface of the eye, constituting only 0.3 % of the total body surface, is extremely sensitive, and it accounts for more than 13 % of all injuries during hostilities. Occupational eye injuries in workers in the agricultural and metallurgical sectors also pose a significant threat. These injuries often lead to serious consequences, including loss of vision or a significant decrease in its functions. In addition, due to hostilities, the number of such injuries and burns has significantly increased, and the medical system is facing new challenges in the treatment of eye injuries. In such difficult circumstances, there is an urgent need to create new combined ophthalmic drugs for the treatment of injuries and burns of the organs of vision. Therefore, it is necessary to develop drugs with anti-inflammatory, antibacterial and antifungal properties, since infections and inflammation that occur after injuries are one of the main complications that can significantly worsen the prognosis of treatment and lead to vision loss.
Aim. Substantiation of the need to develop a new combined drug for ophthalmology that causes anti-inflammatory, antibacterial and antifungal effects.
Materials and methods. Data from sources of professional literature presented in international bibliographic databases (Web of Science, Scopus, PubMed, Chemical Abstracts) were used as the object of research. Methods of systematic analysis and information search were used. In the process of work, a bibliosemantic approach was used to analyze the relationship between key topics and areas of research, as well as methods of descriptive and generalized analysis.
Results. The article analyzes the current state of the pharmaceutical market of ophthalmic drugs, antibacterial, antifungal and antiviral agents. The mechanism of action and features of the use of the main groups of drugs are considered in detail: antibiotics (chloramphenicol, ciprofloxacin, lomefloxacin, ofloxacin, tetracycline, gentamicin, tobramycin, erythromycin, moxifloxacin), sulfonamides (sulfatamide), antiseptics (miramistin) and anti-inflammatory drugs (glucocorticoids and non-steroidal anti-inflammatory drugs).
Conclusions. It was found that with a wide range of available drugs, their therapeutic effect often remains insufficient in complex eye injuries, especially those received during combat operations. Most of available drugs are aimed at treating standard inflammatory processes or certain types of infections, while complex combat injuries require greater pharmacological action and diverse therapy. The need to develop a new combined drug with simultaneous anti-inflammatory, antibacterial and antifungal effects is substantiated. Such drug should provide an effect on several pathogenetic mechanisms, which will reduce the healing of eye tissues, reduce the risk of infectious complications and disability in victims of military operations and accidents in workers in the agricultural and metallurgical sectors.
References
Zhang Y, Kang X, Wu Q, Zheng Z, Ying J, Zhang MN. Explosive eye injuries: characteristics, traumatic mechanisms, and prognostic factors for poor visual outcomes. Mil Med Res. 2023;10(1):3. doi: https://doi.org/10.1186/s40779-022-00438-4
Wang X, Du J, Zhuang Z, Wang ZG, Jiang JX, Yang C. Incidence, casualties and risk characteristics of civilian explosion blast injury in China: 2000-2017 data from the state Administration of Work Safety. Mil Med Res. 2020;7(1):29. doi: https://doi.org/10.1186/s40779-020-00257-5
Verma S, Waikar S, Sharma V, Bhatkoti B, Chauhan R. Ocular trauma in counter insurgency and proxy war environment: Epidemiological study, 1992-2004. Med J Armed Forces India. 2021;77(4):390-6. doi: https://doi.org/10.1016/j.mjafi.2020.02.001
Hamzeh A, Ayoub R, Issa S, Alhalabi N, Sawaf B, Mohsen F, et al. War-related ocular injuries in Damascus during the Syrian Crisis. Injury. 2021;52(2):299-304. doi: https://doi.org/10.1016/j.injury.2020.11.069
Sukkarieh G, Lahoud C, Ghorayeb R, Abi Karam M, Succarieh Y, Saleh M, et al. Characteristics of open eye injuries in the Beirut Port explosion. Injury. 2021;52(9):2601-5. doi: https://doi.org/10.1016/j.injury.2021.07.031
Gensheimer WG, Kerber MT, Blanch RJ. The epidemiology and outcomes of combat ocular trauma among local nationals managed at a deployed military hospital in Afghanistan. Eye (Lond). 2021;35(8):2155-63. doi: https://doi.org/10.1038/s41433-020-01316-w
Colyer MH, Mazzoli RA. Complex ocular trauma outcomes and system capabilities: lessons from a combat zone and implications for national eye trauma care. Eye (Lond). 2021 Aug;35(8):2069-2070. doi: https://doi.org/10.1038/s41433-020-01319-7
Karimi A, Razaghi R, Girkin CA, Downs JC. Ocular biomechanics due to ground blast reinforcement. Comput Methods Programs Biomed. 2021;211:106425. doi: https://doi.org/10.1016/j.cmpb.2021.106425
Lee I, Davis B, Purt B, DesRosiers T. Ocular Trauma and Traumatic Brain Injury on the Battlefield: A Systematic Review After 20 Years of Fighting the Global War on Terror. Mil Med. 2023;188(9-10):2916-23. doi: https://doi.org/10.1093/milmed/usac226
Wróblewska KB, Jadach B, Muszalska-Kolos I. Progress in drug formulation design and delivery of medicinal substances used in ophthalmology. Int J Pharm. 2021;607:121012. doi: https://doi.org/10.1016/j.ijpharm.2021.121012
Contarato JL, Barbalho GN, Cunha-Filho M, Gelfuso GM, Gratieri T. Applying Different Conditions in the OphthalMimic Device Using Polymeric and Hydrogel-Based Hybrid Membranes to Evaluate Gels and Nanostructured Ophthalmic Formulations. Gels. 2024;10(8):538. doi: https://doi.org/10.3390/gels10080538
Novack GD, Robin AL. Ocular Pharmacology. J Clin Pharmacol. 2024;64(9):1068-82. doi: https://doi.org/10.1002/jcph.2451
Plana D, Palmer AC, Sorger PK. Independent Drug Action in Combination Therapy: Implications for Precision Oncology. Cancer Discov. 2022;12(3):606-24. doi: https://doi.org/10.1158/2159-8290.CD-21-0212
Lobiuc A, Pavăl NE, Mangalagiu II, Gheorghiță R, Teliban GC, Amăriucăi-Mantu D, et al. Future Antimicrobials: Natural and Functionalized Phenolics. Molecules. 2023;28(3):1114. doi: https://doi.org/10.3390/molecules28031114
Cabrera-Aguas M, Khoo P, Watson SL. Infectious keratitis: A review. Clin Exp Ophthalmol. 2022;50(5):543-62. doi: https://doi.org/10.1111/ceo.14113
Kalogeropoulos D, Sakkas H, Mohammed B, Vartholomatos G, Malamos K, Sreekantam S, et al. Ocular toxoplasmosis: a review of the current diagnostic and therapeutic approaches. Int Ophthalmol. 2022;42(1):295-321. doi: https://doi.org/10.1007/s10792-021-01994-9
Algarni AM, Guyatt GH, Turner A, Alamri S. Antibiotic prophylaxis for corneal abrasion. Cochrane Database Syst Rev. 2022;5(5):CD014617. doi: https://doi.org/10.1002/14651858.CD014617.pub2
Shariati A, Arshadi M, Khosrojerdi MA, Abedinzadeh M, Ganjalishahi M, Maleki A, et al. The resistance mechanisms of bacteria against ciprofloxacin and new approaches for enhancing the efficacy of this antibiotic. Front Public Health. 2022;10:1025633. doi: https://doi.org/10.3389/fpubh.2022.1025633
Adly ME, Gedawy EM, El-Malah AA, Khalil OM. Design, synthesis and in vitro anticancer activity of some new lomefloxacin derivatives. Sci Rep. 2024;14(1):6175. doi: https://doi.org/10.1038/s41598-024-56313-w
Di Zazzo A, Antonini M, Fernandes M, Varacalli G, Sgrulletta R, Coassin M. A global perspective of pediatric non-viral keratitis: literature review. Int Ophthalmol. 2020;40(10):2771-2788. doi: https://doi.org/10.1007/s10792-020-01451-z
Li J, Qin Y, Zhao C, Zhang Z, Zhou Z. Tetracycline antibiotics: Potential anticancer drugs. Eur J Pharmacol. 2023;956:175949. doi: https://doi.org/10.1016/j.ejphar.2023.175949
Dean L, Kane M. Gentamicin Therapy and MT-RNR1 Genotype. 2015 Apr 29 [updated 2022 Sep 22]. In: Pratt VM, Scott SA, Pirmohamed M, Esquivel B, Kattman BL, Malheiro AJ, editors. Medical Genetics Summaries [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2012.
Schwarz C, Taccetti G, Burgel PR, Mulrennan S. Tobramycin safety and efficacy review article. Respir Med. 2022;195:106778. doi: https://doi.org/10.1016/j.rmed.2022.106778
Platon VM, Dragoi B, Marin L. Erythromycin Formulations-A Journey to Advanced Drug Delivery. Pharmaceutics. 2022;14(10):2180. doi: https://doi.org/10.3390/pharmaceutics14102180
Chen F, Dong Q, Hong W, Zhao J, Li Y. Moxifloxacin monotherapy for treatment of uncomplicated pelvic inflammatory disease: A systematic review and meta-analysis with trial sequential analysis of randomized controlled trials. Pharmacoepidemiol Drug Saf. 2023;32(11):1189-99. doi: https://doi.org/10.1002/pds.5677
Chan VF, Yong AC, Azuara-Blanco A, Gordon I, Safi S, Lingham G, et al. A Systematic review of clinical practice guidelines for infectious and non-infectious conjunctivitis. Ophthalmic Epidemiol. 2022;29(5):473-82. doi: https://doi.org/10.1080/09286586.2021.1971262
Daniel D, Bacchi S, Casson R, Chan W. Sulfonamides in ophthalmology: adverse reactions : Evidence-based use of sulfa drugs in ophthalmology. Int Ophthalmol. 2024;44(1):214. doi: https://doi.org/10.1007/s10792-024-03045-5
Avdieieva L, Balko O, Balko OI, Bakaievych K, Bakaievych Y, Biliaieva O, et al. [Education and science in the period of global crises and conflicts in the 21st century]. Sherman Oaks, California: GS Publishing Services; 2023. 331 р. Available from: https://doi.org/10.51587/9798-9895-14601-2023-016
Rabaan AA, Sulaiman T, Al-Ahmed SH, Buhaliqah ZA, Buhaliqah AA, AlYuosof B, et al. Potential Strategies to Control the Risk of Antifungal Resistance in Humans: A Comprehensive Review. Antibiotics (Basel). 2023;12(3):608. doi: https://doi.org/10.3390/antibiotics12030608
Gaballa SA, Kompella UB, Elgarhy O, Alqahtani AM, Pierscionek B, Alany RG, et al. Corticosteroids in ophthalmology: drug delivery innovations, pharmacology, clinical applications, and future perspectives. Drug Deliv Transl Res. 2021;11(3):866-93. doi: https://doi.org/10.1007/s13346-020-00843-z
Dang DH, Riaz KM, Karamichos D. Treatment of non-infectious corneal injury: review of diagnostic agents, therapeutic medications, and future targets. Drugs. 2022;82(2):145-67. doi: https://doi.org/10.1007/s40265-021-01660-5
Arora S, Surakiatchanukul T, Arora T, Errera MH, Agrawal H, Lupidi M, et al. Retinal toxicities of systemic anticancer drugs. Surv Ophthalmol. 2022;67(1):97-148. doi: https://doi.org/10.1016/j.survophthal.2021.05.007
Downloads
Additional Files
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 L. I. Kucherenko, D. V. Okolzin
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
